title: Efficacy of buspirone for attenuating cocaine and methamphetamine reinstatement in rats.
abstract: BACKGROUND
  There are no approved pharmacotherapies for preventing psychomotor stimulant relapse. The operant reinstatement model has been suggested as a screen for identifying candidate medications. The present study examined if the anxiolytic buspirone could attenuate reinstatement of extinguished responding in Long-Evans rats that previously self-administered intravenous cocaine or methamphetamine.
  
  
  METHODS
  Rats were trained in 2-h daily sessions to self-administer 0.5mg/kg cocaine or 0.1mg/kg methamphetamine infusions followed by 12 days of instrumental extinction. Reinstatement was evoked by 17mg/kg i.p. cocaine primes or response-contingent cocaine-paired cues in cocaine-reinforced rats, and by 1mg/kg i.p. methamphetamine primes or response-contingent methamphetamine-paired cues in methamphetamine-reinforced rats.
  
  
  RESULTS
  Buspirone (1 and 3mg/kg) significantly (p<0.05) attenuated cocaine cue but not cocaine prime reinstatement. Buspirone (1 and 3mg/kg) also significantly attenuated methamphetamine cue reinstatement. Buspirone (3mg/kg) significantly attenuated methamphetamine prime reinstatement. During all reinstatement tests, 3mg/kg buspirone reduced levels of inactive lever pressing relative to those of vehicle, significantly so during the cocaine cue-induced reinstatement tests.
  
  
  CONCLUSIONS
  Given the complexity of buspirone's neuropharmacology consisting of serotonin 5-HT1A receptor partial agonist activity, and dopamine D2, D3 and D4 receptor antagonist effects, it is uncertain which of these activities or their combination is responsible for the present results. Overall, these results suggest that buspirone may reduce the likelihood of relapse to cocaine and methamphetamine use under some conditions, although this speculation must be interpreted with caution given buspirone's similar potency to attenuate inactive-lever responding.
authors: Virginia Commonwealth University School of Medicine, Department of Pharmacology and Toxicology, Richmond, VA 23298-0613, USA. klshelto@vcu.edu
authors: Keith L
authors: KL
authors: Shelton
authors: Elizabeth S
authors: ES
authors: Hendrick
authors: Patrick M
authors: PM
authors: Beardsley
mesh_terms: D000818:Animals; D016739:Behavior, Addictive / Q000188:drug therapy* / Q000523:psychology; D002065:Buspirone / Q000627:therapeutic use*; D003042:Cocaine / Q000008:administration & dosage*; D003216:Conditioning, Operant / Q000187:drug effects / Q000502:physiology; D008297:Male; D008694:Methamphetamine / Q000008:administration & dosage*; D051381:Rats; D020318:Rats, Long-Evans; D011930:Reaction Time / Q000187:drug effects / Q000502:physiology; D012054:Reinforcement, Psychology; D012646:Self Administration; D016896:Treatment Outcome
chemical_list: D008694:Methamphetamine; D003042:Cocaine; D002065:Buspirone
references: Behav Pharmacol. 2005 May;16(3):187-91
references: 15864074
references: Psychopharmacology (Berl). 1992;108(1-2):85-92
references: 1357711
references: Neuroscience. 2004;128(1):121-30
references: 15450359
references: Addict Biol. 2010 Jul;15(3):227-49
references: 20456287
references: Int J Neuropsychopharmacol. 2013 Mar;16(2):445-58
references: 22827916
references: Psychopharmacology (Berl). 2003 Jul;168(1-2):31-41
references: 12721778
references: Psychopharmacology (Berl). 2003 Jul;168(1-2):109-117
references: 12520312
references: Bull Am Acad Psychiatry Law. 1986;14(2):105-22
references: 2873851
references: Psychopharmacology (Berl). 1993;110(3):280-6
references: 7831420
references: Behav Pharmacol. 1994 Oct;5(6):591-598
references: 11224238
references: Behav Pharmacol. 2002 Nov;13(7):511-23
references: 12409990
references: J Psychopharmacol. 2011 Feb;25(2):263-73
references: 20142301
references: Psychopharmacology (Berl). 2001 Oct;157(4):340-8
references: 11605092
references: Pharmacol Biochem Behav. 1990 Jan;35(1):117-20
references: 2315348
references: Psychopharmacology (Berl). 2001 Apr;155(1):18-26
references: 11374332
references: Naunyn Schmiedebergs Arch Pharmacol. 2004 Jun;369(6):576-82
references: 15138661
references: Biol Psychiatry. 1985 Sep;20(9):971-9
references: 2862927
references: Pharmacol Biochem Behav. 1997 Oct;58(2):311-5
references: 9300585
references: Psychopharmacology (Berl). 2003 Jul;168(1-2):118-123
references: 12420155
references: Eur J Pharmacol. 1986 Sep 23;129(1-2):123-30
references: 2876903
references: Eur J Pharmacol. 2011 Jun 1;659(2-3):187-92
references: 21466803
references: Psychopharmacology (Berl). 2010 Jun;210(2):169-77
references: 19859697
references: J Pharmacol Exp Ther. 1997 Aug;282(2):1011-9
references: 9262370
references: Prog Neuropsychopharmacol Biol Psychiatry. 1988;12(2-3):233-9
references: 3387585
references: J Subst Abuse Treat. 2011 Apr;40(3):255-64
references: 21266301
references: Contemp Clin Trials. 2012 Sep;33(5):993-1002
references: 22613054
references: Psychopharmacology (Berl). 2003 Jul;168(1-2):3-20
references: 12402102
references: Psychopharmacology (Berl). 1993;111(1):55-61
references: 7870934
references: Pharmacol Biochem Behav. 2008 Sep;90(3):434-40
references: 18456312
references: Addict Behav. 2008 Dec;33(12):1581-9
references: 18790574
references: Behav Pharmacol. 1997 Dec;8(8):699-706
references: 9832955
references: Neurosci Biobehav Rev. 2011 May;35(6):1419-49
references: 21402098
references: Drug Alcohol Depend. 2006 Jan 4;81(1):63-70
references: 16005579
references: J Physiol Pharmacol. 2000 Dec;51(4 Pt 2):833-46
references: 11220492
references: Psychopharmacology (Berl). 2003 Jul;168(1-2):146-154
references: 12529808
references: Pharmacol Biochem Behav. 1990 Jul;36(3):635-8
references: 2377664
references: J Consult Clin Psychol. 1996 Apr;64(2):366-79
references: 8871421
references: Neuropsychopharmacology. 2004 Apr;29(4):660-8
references: 14627998
references: Psychopharmacology (Berl). 2005 Nov;183(1):118-26
references: 16184376
references: Eur J Pharmacol. 1998 Jul 10;352(2-3):179-87
references: 9716353
references: Arch Gen Psychiatry. 2009 Jan;66(1):88-94
references: 19124692
references: Behav Pharmacol. 1991 Feb;2(1):3-14
references: 11224042
references: Eur J Pharmacol. 1997 Aug 27;333(2-3):113-22
references: 9314023
references: Naunyn Schmiedebergs Arch Pharmacol. 1993 Oct;348(4):339-46
references: 7904048
references: Curr Top Med Chem. 2006;6(18):1971-85
references: 17017968
references: Am J Public Health. 2001 Jul;91(7):1107-13
references: 11441739
references: CNS Drug Rev. 2007 Summer;13(2):240-59
references: 17627675
references: Synapse. 2001 Jan;39(1):32-41
references: 11071707
references: Neuropharmacology. 1997 Mar;36(3):373-81
references: 9175616
references: J Pharmacol Exp Ther. 1999 Oct;291(1):239-50
references: 10490910
references: Pharmacol Toxicol. 1991 Sep;69(3):149-56
references: 1796057
references: Prog Neuropsychopharmacol Biol Psychiatry. 2007 Apr 13;31(3):593-9
references: 17270333
references: Psychopharmacology (Berl). 1992;108(3):289-94
references: 1355922
references: Pharmacol Biochem Behav. 1993 May;45(1):179-83
references: 8516356
references: J Pharmacol Exp Ther. 2010 Aug;334(2):556-65
references: 20494958
references: J Anxiety Disord. 2012 Jun;26(5):583-9
references: 22440391
references: J Neurochem. 1999 May;72(5):2022-31
references: 10217280
references: Psychopharmacology (Berl). 1993;110(4):390-4
references: 7870907
references: Psychopharmacology (Berl). 2006 Nov;189(1):1-16
references: 17019567
references: Prog Neurobiol. 2007 Feb;81(3):133-78
references: 17316955
references: Neuropharmacology. 2011 Sep;61(3):421-32
references: 21466815
references: Pharmacol Biochem Behav. 2000 Oct;67(2):363-9
references: 11124402
references: Pharmacol Biochem Behav. 1996 Jun;54(2):517-23
references: 8743617
references: Psychopharmacology (Berl). 2011 Nov;218(1):29-37
references: 21336579
references: Ann N Y Acad Sci. 2010 Feb;1187:4-34
references: 20201845
references: Int J Neuropsychopharmacol. 2007 Apr;10(2):167-81
references: 16426478
references: J Clin Psychiatry. 2010;71 Suppl E1:e02
references: 20371029
references: Pharmacol Rep. 2011;63(6):1310-5
references: 22358079
references: Eur J Pharmacol. 2004 Aug 16;497(1):35-40
references: 15302593
references: Pharmacol Biochem Behav. 1994 Jun;48(2):465-71
references: 8090816